Developing Novel Precision Oncology Therapeutics

We are a clinical stage global biopharmaceutical company developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need.

About Us

Clinical Stage Assets

Taletrectinib
AB-106

ROS1 fusion positive non-small cell lung cancer

Phase 2

mIDH1 inhibitor
AB-218

Lower-grade glioma, cholangiocarcinoma and other tumors

Phase 2

AXL inhibitor
AB-329

Overcoming checkpoint inhibitor resistance in various tumors

Phase 1

Our Pipeline

Recent News

More News